1607448-75-8

Basic information

• Product Name: 2-((4-(1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)quinolin-3-ol
• Synonyms: 2-((4-(1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)quinolin-3-ol
• CAS NO: 1607448-75-8
• Molecular Weight: 408.459
• Mol File: 1607448-75-8.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 2-((4-(1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)quinolin-3-ol(CAS DataBase Reference)
• NIST Chemistry Reference: 2-((4-(1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)quinolin-3-ol(1607448-75-8)
• EPA Substance Registry System: 2-((4-(1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)quinolin-3-ol(1607448-75-8)

Safety Data

• Hazardous Substances Data: 1607448-75-8(Hazardous Substances Data)

Upstream product

• 529-23-7 o-aminobenzaldehyde 
• 847547-93-7 3-(methoxymethoxy)-2-methylquinoline 
• 613-19-4 3-hydroxy-quinaldine 
• 84689-36-1 3-methoxy-2-methylquinoline 

Downstream Products

• 1607448-71-4 3-(methoxy-¹¹C)-2-((4-(1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)quinoline 

Relevant articles and documents

Synthesis of fluorine-containing phosphodiesterase 10A (PDE10A) inhibitors and the in vivo evaluation of F-18 labeled PDE10A PET tracers in rodent and nonhuman primate

A series of fluorine-containing PDE10A inhibitors were designed and synthesized to improve the metabolic stability of [11C]MP-10. Twenty of the 22 new analogues had high potency and selectivity for PDE10A: 18a-j, 19d-j, 20a-b, and 21b had IC50 values 18F]18a-e, [18F]18g, and [18F]20a were radiosynthesized by 18F-introduction onto the quinoline rather than the pyrazole moiety of the MP-10 pharmacophore and performed in vivo evaluation. Biodistribution studies in rats showed ～2-fold higher activity in the PDE10A-enriched striatum than nontarget brain regions; this ratio increased from 5 to 30 min postinjection, particularly for [18F]18a-d and [18F]20a. MicroPET studies of [18F]18d and [18F]20a in nonhuman primates provided clear visualization of striatum with suitable equilibrium kinetics and favorable metabolic stability. These results suggest this strategy may identify a 18F-labeled PET tracer for quantifying the levels of PDE10A in patients with CNS disorders including Huntington's disease and schizophrenia.